On the fly News and insights, exclusive to thefly.com

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

17:37
10/20/17
10/20
17:37
10/20/17
17:37

DBV sinks following peanut allergy trial miss, Aimmune soars

Shares of DBV Technologies (DBVT) are sinking after the company announced that its Phase III study in peanut allergic patients ages four to 11 years missed the primary endpoint. The stock is down 46%, or $22.35, to $25.72 in after-hours trading. DBV said it will continue ongoing discussions with the FDA and plans to proceed with the Biologics License Application preparation process. Shares of Aimmune Therapeutics (AIMT), a company also in Phase III with a peanut allergy treatment, are soaring. The stock is up 56%, or $14.24, to $39.90.

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

  • 06

    Nov

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.